Women diagnosed with breast cancer are at an increased risk of contracting ovarian cancer due to the presence of same gene that triggers both cancers.
"Genes are responsible for cancer. Owing to the rise in the incidence of breast cancer, we have observed that there is a considerable increase in cases of ovarian cancer as well in the past few years. Even at AIIMS there have been many cases where a female patient has been diagnosed with both," Dr Ray told IANS.
Breast Cancer Management: Advances
The crab that invades the breast is no more a fear factor with all the advancements that medical science and customized protocols can fight breast cancer. the recent developments in the management of breast cancer.
Advertisement
‘Rise in breast cancer leads to more ovarian cancer.
’
Tweet it Now
BRCA1 and BRCA2 are human genes that produce tumour suppressor proteins. However, when either of these genes is mutated -- meaning it doesn't function correctly -- the damage to the DNA may not be repaired properly. As a result, cells are more likely to develop additional genetic alterations that can lead to cancer.
"There are two types of genes -- BRCA1 and BRCA2 -- which are responsible for both breast and ovarian cancer. Dysfunction of these two genes increases the chances of getting diagnosed with both the cancers. An individual with breast cancer, therefore, remains at risk of facing ovarian cancer and vice versa," Dr Ray noted.
![Ovarian Cancer]( "Ovarian Cancer")
Ovarian cancer affects both the ovaries and is referred to as the ''silent killer'' as the symptoms go unnoticed until the disease advances.
"If one has breast cancer, there are 30-35 per cent chances of also having ovarian cancer. And if the person has ovarian cancer, there are 10-15 per cent chances of getting diagnosed with breast cancer," Dr Mala Srivastava, oncologist, Sir Ganga Ram Hospital, noted.
Specific inherited mutations in BRCA1 and BRCA2 most notably increase the risk of breast and ovarian cancer, but they have also been associated with increased risks of several additional types of the disease like fallopian tube cancer, peritoneal cancer, colorectal cancer and pancreatic cancer.
Women who have inherited mutations in BRCA1 and BRCA2 tend to develop breast and ovarian cancers at younger ages than those without these mutations.
Although presumed to be more common among women above 50, Dr Ray noted that both breast and ovarian cancer cases are increasing among women below 35 as well.
"This is owing to poor lifestyle habits. And this is not confined to any particular economic class. A sedentary lifestyle further escalates it," he added.
Since both cancers are related to genetics, medical experts suggested that women should start screening and gene-testing at an early age.
"For, say, if one or two family members had breast or ovarian cancer then all the women in that family should be tested for BRCA 1 and BRCA 2. Secondly, the screening for both breast and ovarian cancer should start early in life. Suppose a woman's mother had breast cancer at the age of 45, then she should start mammography at the age of 35," Dr Srivastava pointed out.
In India, however, gene tests are still costly which is why many women fail to get diagnosed in time. Dr Srivastava said that a gene test would cost around Rs 25,000 to Rs 26,000.
"In India, almost 90 per cent patients come to a doctor when in an advanced stage because they don't get detected at an early stage. The main reason is that the symptoms of ovarian cancers are very vague. Despite all types of high-tech surgeries, the survival rate is less than 30 per cent," Dr Ray added.
The doctors claimed that if detected early, both cancers are curable.
"Now-a-days, treatment is very good. If a woman diagnosed with breast cancer is detected and treated at an early stage, there are less chances of her having ovarian cancer," Dr Srivastava explained.
According to a latest ICMR-Lancet report, breast cancer is the leading cancer among Indian women. States like Kerala, Punjab, Tamil Nadu, Delhi, Maharashtra, Karnataka, and Haryana were found to have the majority of cases.
The report also stated that ovarian cancer has the sixth-highest incidence rate with the majority in states like Kerala, Delhi, Arunachal Pradesh and Punjab.
Source: IANS
Ovarian Cancer
Ovarian cancer affects both the ovaries and is referred to as the ''silent killer'' as the symptoms go unnoticed until the disease advances.
Advertisement
"If one has breast cancer, there are 30-35 per cent chances of also having ovarian cancer. And if the person has ovarian cancer, there are 10-15 per cent chances of getting diagnosed with breast cancer," Dr Mala Srivastava, oncologist, Sir Ganga Ram Hospital, noted.
Specific inherited mutations in BRCA1 and BRCA2 most notably increase the risk of breast and ovarian cancer, but they have also been associated with increased risks of several additional types of the disease like fallopian tube cancer, peritoneal cancer, colorectal cancer and pancreatic cancer.
Women who have inherited mutations in BRCA1 and BRCA2 tend to develop breast and ovarian cancers at younger ages than those without these mutations.
Although presumed to be more common among women above 50, Dr Ray noted that both breast and ovarian cancer cases are increasing among women below 35 as well.
"This is owing to poor lifestyle habits. And this is not confined to any particular economic class. A sedentary lifestyle further escalates it," he added.
Since both cancers are related to genetics, medical experts suggested that women should start screening and gene-testing at an early age.
"For, say, if one or two family members had breast or ovarian cancer then all the women in that family should be tested for BRCA 1 and BRCA 2. Secondly, the screening for both breast and ovarian cancer should start early in life. Suppose a woman's mother had breast cancer at the age of 45, then she should start mammography at the age of 35," Dr Srivastava pointed out.
In India, however, gene tests are still costly which is why many women fail to get diagnosed in time. Dr Srivastava said that a gene test would cost around Rs 25,000 to Rs 26,000.
"In India, almost 90 per cent patients come to a doctor when in an advanced stage because they don't get detected at an early stage. The main reason is that the symptoms of ovarian cancers are very vague. Despite all types of high-tech surgeries, the survival rate is less than 30 per cent," Dr Ray added.
The doctors claimed that if detected early, both cancers are curable.
"Now-a-days, treatment is very good. If a woman diagnosed with breast cancer is detected and treated at an early stage, there are less chances of her having ovarian cancer," Dr Srivastava explained.
According to a latest ICMR-Lancet report, breast cancer is the leading cancer among Indian women. States like Kerala, Punjab, Tamil Nadu, Delhi, Maharashtra, Karnataka, and Haryana were found to have the majority of cases.
The report also stated that ovarian cancer has the sixth-highest incidence rate with the majority in states like Kerala, Delhi, Arunachal Pradesh and Punjab.
Source: IANS
Quiz on Ovarian Cancer / Cancer of the Ovary
Ovarian cancer is a cancer that does not produce definite symptoms. Here are a few questions that you could attempt to answer to check your knowledge on ovarian cancer.
Advertisement
 Breast Cancer Risk Assessment CalculatorBreast Cancer Risk Assessment Calculator predicts the risk for breast cancer. Find list of breast cancer facts and more information on signs and symptoms of breast cancer and mammography. | Advertisement
|
Advertisement
Recommended Readings
Latest Cancer News
The new study uncovers the efficacy of fixed-duration combination treatment in patients with high-risk leukemia.
The approvals of pipeline drugs such as momelotinib and Vonjo for myelofibrosis (a rare type of blood cancer) over some time will handle the critical unmet needs.
New study highlights the dual role that blood vessels can play in cancer immunotherapy and eliciting anti-tumor immune responses or even preventing breast cancer spread.
New study evaluated the association between exposure to the chemical agent orange and the development of blood cancer with increased bleeding and blood clot formation.
Study suggests two-year immunotherapy treatment for advanced lung cancer may be reasonable